CZClive S. Zent

Clive S. Zent

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clive S. Zent has a total of 291 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report

    by Fatma F. Shakarchi, Joseph A. Chacko, Joseph G. Chacko, Rangaswamy Govindarajan, Clive S. Zent, Sami H. Uwaydat

  • Open Access

    Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemia

    by Charles C. Chu, Clare B. Heffernan, Nydia C. Jaimes‐Delgadillo, Christine A. Herne, Jennifer E. Bruno, Andrea M. Baran, John M. Ashton, Timothy R. Mosmann, Paul M. Barr, Ronald P. Taylor, et al.

    Anti‐CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high‐frequency low‐dose (HFLD) rituximab for 1 week followed by the addition of acalabrutinib. Low‐dose rituximab (intravenous infusion of 25 mg over 1 h) decreased the circulating CLL cell count by 85% with no additional changes during infusion of the next 25 mg of rituximab. Limited clearance of CLL cells was not attributable to low concentrations of rituximab or complement and was most likely caused by exhaustion of innate immune cytotoxicity as previously described for larger rituximab doses. Circulating CLL counts and CD20 levels rebounded by 48 h when subcutaneous administration of 50 mg of rituximab caused a small but significant decrease in CLL cell counts. Administration of 100 mg of rituximab in the first week of therapy decreased palpable lymphadenopathy by 66%. Addition of acalabrutinib, a second‐generation Bruton tyrosine kinase inhibitor (BTKi), on Day 8 of treatment was followed by decreases in CLL cell expression of MS4A1 coding for CD20, CD20 levels, and CLL cell sensitivity to rituximab‐induced antibody‐dependent cellular phagocytosis. Based on these data and previous reports, we propose that rituximab therapy in CLL patients is optimized by HFLD regimens, which achieve maximum CLL cell clearance at dosing intervals sufficient for recovery of immune cytotoxicity. Our data also suggest that the efficacy of rituximab, and possibly other CD20‐targeting mAbs, could be decreased by the addition of acalabrutinib or other BTKi.

  • Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant

    by Clive S Zent, Enrico Tiacci, Robert J. Kreitman, Tamar Tadmor, Martin S. Tallman, Bernhard J. Wörmann, Leslie A Andritsos, Evgeny Arons, Versha Banerji, Jacqueline Claudia Barrientos, et al.

    Hairy cell leukemia (HCL) and hairy cell leukemia variant (HCLv) are distinct, rare, chronic splenic B cell lymphomas/leukemias that partially overlap in clinico-pathological presentation but differ in genetic basis, prognosis, and management. HCL is caused by the BRAF-V600E kinase-activating mutation in >95% of patients, usually has excellent responses to chemotherapy with purine analogs and is also amenable to BRAF inhibitor-based targeted treatments. In contrast, HCLv lacks BRAF-V600E, requires combined therapy with purine analogs plus rituximab and generally shows less-durable responses. Here, an international team of hematologists expert on these rare diseases was convened by the Hairy Cell Leukemia Foundation to update the previous guidelines (published in 2017) by providing a summary of current methods to diagnose and manage patients with HCL and HCLv, as well as a prospective on newer targeted therapies to further improve outcome.


  • Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti‐CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

    by Jennifer E. Bruno, Christine A. Herne, Andrea M. Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Tim R. Mosmann, Clive S. Zent, Charles C. Chu


  • Open Access

    Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

    by Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Jacqueline Barrientos, Seema A. Bhat, James Blachly, Alessandro Broccoli, Timothy Call, et al.


  • Open Access

    Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

    by Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, et al.

    Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Owing to the synergistic antitumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment. We conducted a phase 1/2 clinical trial to determine the safety and efficacy of venetoclax in combination with umbralisib and the anti-CD20 monoclonal antibody, ublituximab, (U2-VeN) in patients with relapsed/refractory CLL (N = 46) and Richter transformation (N = 5). After 12 cycles, treatment was stopped for patients with CLL who achieved undetectable minimal residual disease (uMRD). Adverse events of special interest included diarrhea in 50% of patients (11% grade 3/4), and aspartate aminotransferase and/or alanine aminotransferase elevation in 15 patients (33%), with 3 (7%) grade 3/4. There were no cases of tumor lysis syndrome related to venetoclax, with outpatient initiation in 96% of patients. The intent-to-treat overall response rate for CLL was 98% with best response of 100% in evaluable patients (42% complete responses). The end-of-treatment rate of uMRD at 10−4 in bone marrow was 77% (30/39), including a 71% uMRD rate among 14 patients refractory to prior BTK inhibitor. Time-limited venetoclax and U2 is safe and highly effective combination therapy for patients with relapsed/refractory CLL including those who have been previously treated with covalent BTK inhibitors. This trial was registered on www.clinicaltrials.gov as #NCT03379051.


  • Long‐term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma

    by Michael T. Brady, Nathan Laniewski, Myla Strawderman, Charles C. Chu, Preshetha Kanagaiah, Mark Y. Sangster, David J. Topham, Jonathan W. Friedberg, Clive S. Zent


  • Open Access

    Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

    by Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr

    Bruton tyrosine kinase inhibitors are an effective therapeutic agent for previously untreated patients with chronic lymphocytic leukemia but require indefinite treatment that can result in cumulative toxicities. Novel combinations of agents that provide deep remissions could allow for fixed duration therapy. Acalabrutinib, unlike ibrutinib, does not inhibit anti-CD20 monoclonal antibody-dependent cellular phagocytosis, making it a suitable partner drug to rituximab. Using standard dosing (375 mg/m2) of rituximab causes loss of target membrane CD20 cells and exhaustion of the finite cytotoxic capacity of the innate immune system. Alternatively, using high-frequency, low-dose (HFLD), subcutaneous rituximab limits loss of CD20 and allows for self-administration at home. The combination of HFLD rituximab 50 mg administered twice a week for 6 cycles of 28 days with the addition of acalabrutinib starting in week 2 was evaluated in a phase II study of 38 patients with treatment naive chronic lymphocytic leukemia. Patients achieving a complete response with undetectable minimal residual disease after 12 or 24 cycles of acalabrutinib could stop therapy. All patient responded, including one with a complete response with undetectable minimal residual disease in the peripheral blood and bone marrow at 12 months who stopped therapy. At a median follow-up of 2.3 years 2 patients with high-risk features have progressed while on acalabrutinib monotherapy. We conclude that HFLD rituximab in combination with acalabrutinib is an effective and tolerable self-administered home combination that provides a platform to build upon regimens that may more reliably allow for fixed-duration therapy. This trial was registered at www.clinicaltrials.gov #NCT03788291.


  • Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

    by Jeremiah E. Moore, Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea M. Baran, Sally A. Quataert, Timothy R. Mosmann, Ronald P. Taylor, Danielle S. Wallace, et al.


  • Open Access

    Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders

    by Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E. Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K. Aktas, Clive S. Zent, et al.

    Background: There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting. Methods and Results: The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias—atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia—were identified using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine kinase inhibitor (BTKi), mainly ibrutinib/non‐BTKi treatment versus no treatment. Median age was 64 (54–72) years, and 42% were women. The overall rate of any arrhythmia at 5 years following the initiation of BTKi was (61%) compared with (18%) without treatment. Atrial fibrillation/flutter was the most common type of arrhythmia accounting for 41%. Multivariate analysis showed that BTKi treatment was associated with a 4.3‐fold ( P P P P <0.001). Conclusions: Our study identifies a high burden of arrhythmic events after initiation of treatment, which is most pronounced among patients treated with the BTKi ibrutinib. Patients undergoing treatments for lymphoma may benefit from prospective focused cardiovascular monitoring prior, during, and after treatment regardless of arrhythmia history.